Open Nav

Please submit your session questions in advance at

Congenica Ltd

  • David Atkins, Congenica

Congenica aspires to fully enable the routine use of genomic medicine to support the diagnosis and characterisation of disease like rare disease and cancer using complex genomic data. The reduction DNA sequencing cost has made analysis of a patient’s genome a reality and the challenge now is the data interpretation. Congenica a provider of a diagnostic decision support software platform, Sapientia, which enable clinicians to interrogate the human genome to identify disease-causing variants.

A diagnosis removes the fear of the unknown, allowing a patient’s family to deal with the known and make informed decisions. There is also the potential for healthcare savings by avoiding unnecessary appointments, tests and interventions.

HQ in Cambridge, UK founded by the Wellcome Trust Sanger Institute and leaders from the NHS. Congenica was recently named as the genomic software partner for the NHS. Congenica is currently expanding into markets in US, China and beyond.

  • Date:Tuesday, February 12
  • Time:10:15 AM - 10:30 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23536
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Introduce Congenica to US investors
  • Company
  • Company HQ City:Cambridge
  • Company HQ Country:United Kingdom
  • Total Amount Raised to Date, in All Rounds:$30 million
  • Size of Last Investment Round:$15 million
  • Previous and Current Investors:Cambridge Innovation Capital, Parkwalk Advisors, Amadeus Capital
  • CEO/Top Company Official:David Atkins
  • Year Founded:2014
  • Main Therapeutic Focus:Digital Health
  • Lead Product in Development:Sapientia, Clinical Decision Support Platform
  • Development Phase of Primary Product:Multiple Products in Market
  • Additional Information/Comments:Congenica is a leading UK genomics provider that has established a strong market presence in the UK and increasingly in China, The business is now seeking strategic partners in the US to support market penetration in the US after initial market success with a number of clients.
David Atkins